Trial Outcomes & Findings for Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia (NCT NCT00587171)

NCT ID: NCT00587171

Last Updated: 2016-07-13

Results Overview

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.

Recruitment status

TERMINATED

Study phase

PHASE3

Target enrollment

19 participants

Primary outcome timeframe

17 weeks

Results posted on

2016-07-13

Participant Flow

Nineteen subjects were recruited by 7 community based or institutional based sites between April 2008 and March 2009.

At enrollment, subjects were required to have been treated with at least 16 weeks of single vision spectacles (if needed) or until visual acuity was documented to be stable. The child must have had access to a computer on a daily basis.

Participant milestones

Participant milestones
Measure
Active
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Overall Study
STARTED
9
10
Overall Study
COMPLETED
8
9
Overall Study
NOT COMPLETED
1
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Active
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Overall Study
Lost to Follow-up
1
1

Baseline Characteristics

Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Active
n=9 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=10 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Total
n=19 Participants
Total of all reporting groups
Age, Continuous
10.1 years
STANDARD_DEVIATION 2.1 • n=5 Participants
10.0 years
STANDARD_DEVIATION 1.8 • n=7 Participants
10.0 years
STANDARD_DEVIATION 1.9 • n=5 Participants
Age, Customized
7 years old
1 participants
n=5 Participants
2 participants
n=7 Participants
3 participants
n=5 Participants
Age, Customized
8 years old
2 participants
n=5 Participants
1 participants
n=7 Participants
3 participants
n=5 Participants
Age, Customized
9 years old
2 participants
n=5 Participants
2 participants
n=7 Participants
4 participants
n=5 Participants
Age, Customized
10 years old
1 participants
n=5 Participants
0 participants
n=7 Participants
1 participants
n=5 Participants
Age, Customized
11 years old
0 participants
n=5 Participants
4 participants
n=7 Participants
4 participants
n=5 Participants
Age, Customized
12 years old
3 participants
n=5 Participants
1 participants
n=7 Participants
4 participants
n=5 Participants
Sex: Female, Male
Female
6 Participants
n=5 Participants
5 Participants
n=7 Participants
11 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
5 Participants
n=7 Participants
8 Participants
n=5 Participants
Race/Ethnicity, Customized
White
3 participants
n=5 Participants
5 participants
n=7 Participants
8 participants
n=5 Participants
Race/Ethnicity, Customized
Black/African American
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
6 participants
n=5 Participants
4 participants
n=7 Participants
10 participants
n=5 Participants
Region of Enrollment
United States
9 participants
n=5 Participants
10 participants
n=7 Participants
19 participants
n=5 Participants
Cause of Amblyopia
Anisometropia
4 participants
n=5 Participants
5 participants
n=7 Participants
9 participants
n=5 Participants
Cause of Amblyopia
Strabismus
0 participants
n=5 Participants
2 participants
n=7 Participants
2 participants
n=5 Participants
Cause of Amblyopia
Strabismus and anisometropia
5 participants
n=5 Participants
3 participants
n=7 Participants
8 participants
n=5 Participants
Distance visual acuity in amblyopic eye
20/100 (48 to 52 letters) (worse)
2 participants
n=5 Participants
2 participants
n=7 Participants
4 participants
n=5 Participants
Distance visual acuity in amblyopic eye
20/80 (53 to 57 letters)
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants
Distance visual acuity in amblyopic eye
20/63 (58 to 62 letters)
1 participants
n=5 Participants
1 participants
n=7 Participants
2 participants
n=5 Participants
Distance visual acuity in amblyopic eye
20/50 (63 to 67 letters)
4 participants
n=5 Participants
2 participants
n=7 Participants
6 participants
n=5 Participants
Distance visual acuity in amblyopic eye
20/40 (68 to 72 letters) (best)
2 participants
n=5 Participants
4 participants
n=7 Participants
6 participants
n=5 Participants
Mean (SD) Distance Visual Acuity in Amblyopic Eye
62.3 letters
STANDARD_DEVIATION 6.8 • n=5 Participants
61.9 letters
STANDARD_DEVIATION 7.9 • n=7 Participants
62.1 letters
STANDARD_DEVIATION 7.2 • n=5 Participants
Distance visual acuity in fellow eye
20/40 (68 to 72 letters) (worse)
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Distance visual acuity in fellow eye
20/32 (73 to 77 letters)
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Distance visual acuity in fellow eye
20/25 (78 to 82 letters)
2 participants
n=5 Participants
2 participants
n=7 Participants
4 participants
n=5 Participants
Distance visual acuity in fellow eye
20/20 (83 to 87 letters)
4 participants
n=5 Participants
5 participants
n=7 Participants
9 participants
n=5 Participants
Distance visual acuity in fellow eye
20/16 (88 to 92 letters) (best)
3 participants
n=5 Participants
3 participants
n=7 Participants
6 participants
n=5 Participants
Mean (SD) Distance Visual Acuity in Fellow Eye
85.3 letters
STANDARD_DEVIATION 3.6 • n=5 Participants
86.2 letters
STANDARD_DEVIATION 4.0 • n=7 Participants
85.8 letters
STANDARD_DEVIATION 3.8 • n=5 Participants
Mean (SD) Intereye Acuity Difference
23.0 letters
STANDARD_DEVIATION 6.5 • n=5 Participants
24.3 letters
STANDARD_DEVIATION 8.8 • n=7 Participants
23.7 letters
STANDARD_DEVIATION 7.6 • n=5 Participants
Randot Preschool stereoacuity
40 arcsec
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Randot Preschool stereoacuity
60 arcsec
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Randot Preschool stereoacuity
100 arcsec
2 participants
n=5 Participants
4 participants
n=7 Participants
6 participants
n=5 Participants
Randot Preschool stereoacuity
200 arcsec
3 participants
n=5 Participants
2 participants
n=7 Participants
5 participants
n=5 Participants
Randot Preschool stereoacuity
400 arcsec
1 participants
n=5 Participants
2 participants
n=7 Participants
3 participants
n=5 Participants
Randot Preschool stereoacuity
800 arcsec
3 participants
n=5 Participants
2 participants
n=7 Participants
5 participants
n=5 Participants
Randot Preschool stereoacuity
>800 arcsec
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Randot Preschool stereoacuity
Failed pretest
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants

PRIMARY outcome

Timeframe: 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/80 (53 to 57 letters) (worse)
0 participants
1 participants
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/63 (58 to 62 letters)
1 participants
0 participants
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/50 (63 to 67 letters)
0 participants
2 participants
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/40 (68 to 72 letters)
3 participants
1 participants
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/32 (73 to 77 letters)
0 participants
2 participants
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/25 (78 to 82 letters)
2 participants
2 participants
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
20/20 (83 to 87 letters) (best)
2 participants
1 participants

PRIMARY outcome

Timeframe: 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Mean (SD): Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
75.6 letters
Standard Deviation 9.7
72.0 letters
Standard Deviation 9.6

PRIMARY outcome

Timeframe: Baseline to 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
>=1 letter worse
0 participants
0 participants
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
0 letters
0 participants
0 participants
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
1 to 4 letters better
0 participants
2 participants
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
5 to 9 letters better
4 participants
4 participants
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
10 to 14 letters better
1 participants
2 participants
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
>=15 letters better
3 participants
1 participants

PRIMARY outcome

Timeframe: Baseline to 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Mean (SD) of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
12.0 letters
Standard Deviation 5.3
8.8 letters
Standard Deviation 5.3

SECONDARY outcome

Timeframe: 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Distribution of Fellow Eye Visual Acuity at 17 Weeks
20/25 (78 to 82 letters) (worse)
2 participants
0 participants
Distribution of Fellow Eye Visual Acuity at 17 Weeks
20/20 (83 to 87 letters)
1 participants
4 participants
Distribution of Fellow Eye Visual Acuity at 17 Weeks
20/16 (88 to 92 letters)
5 participants
2 participants
Distribution of Fellow Eye Visual Acuity at 17 Weeks
20/12 (93 to 97 letters) (best)
0 participants
3 participants

SECONDARY outcome

Timeframe: 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Mean (SD) of Fellow Eye Visual Acuity at 17 Weeks
86.5 letters
Standard Deviation 4.1
89.8 letters
Standard Deviation 3.6

SECONDARY outcome

Timeframe: Baseline to 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
Within 4 letters
7 participants
7 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
5 to 9 letters better
1 participants
2 participants

SECONDARY outcome

Timeframe: Baseline to 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Mean (SD) of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
0.4 letters
Standard Deviation 2.8
2.9 letters
Standard Deviation 2.7

SECONDARY outcome

Timeframe: 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Mean (SD) of Intereye Visual Acuity at 17 Weeks
10.9 letters
Standard Deviation 9.2
17.8 letters
Standard Deviation 9.4

SECONDARY outcome

Timeframe: Baseline to 17 weeks

Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Mean (SD) of Change in Intereye Visual Acuity From Baseline to 17 Weeks
11.6 letters
Standard Deviation 4.2
5.9 letters
Standard Deviation 5.0

SECONDARY outcome

Timeframe: 17 weeks

The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc. This Stereotest is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score \>800 (the worst), 800, 400, 200, 100, 60, or 40 (the best) seconds of arc. If two shapes are identified correctly the patient progresses to the next lower stereoacuity level. A failed test occurs when the patient cannot identify any shapes.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=9 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Distribution of Randot Preschool Stereoacuity at 17 Weeks
40 arcsec (best)
2 participants
1 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
60 arcsec
1 participants
0 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
100 arcsec
2 participants
1 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
200 arcsec
0 participants
4 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
400 arcsec
2 participants
0 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
800 arcsec
1 participants
1 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
>800 arcsec (worse)
0 participants
1 participants
Distribution of Randot Preschool Stereoacuity at 17 Weeks
Failed pretest
0 participants
1 participants

SECONDARY outcome

Timeframe: Baseline to 17 weeks

The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc on patients as young as 2 years of age. This Stereotest is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score \>800 (the worst), 800, 400, 200, 100, 60, or 40 (the best) seconds of arc. If two shapes are identified correctly the patient progresses to the next lower stereoacuity level. A failed test occurs when the patient cannot identify any shapes.

Outcome measures

Outcome measures
Measure
Active
n=8 Participants
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Control
n=8 Participants
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Distribution of Change in Randot Preschool Steroacuity From Baseline to 17 Weeks
2 or more levels worse
1 participants
2 participants
Distribution of Change in Randot Preschool Steroacuity From Baseline to 17 Weeks
Within 1 level
4 participants
4 participants
Distribution of Change in Randot Preschool Steroacuity From Baseline to 17 Weeks
2 or more levels better
3 participants
2 participants

Adverse Events

Active

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Raymond Kraker, M.S.P.H.

Jaeb Center for Health Research

Phone: 813-975-8690

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place